The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
The company is seeking NY State approval for its lab, which would allow it to offer both tests as LDTs, hopefully by the end of this year or early next.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
